Jianqin Lu

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 21

Top Venues

Nature communications

Pharmaceutics

ACS nano

Genes and immunity

The University of Arizona

University of Pittsburgh (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Arizona Apr 01 2019

United States

Assistant Professor

UCLA - Mar 31 2019

United States

Postdoctoral Scholar :: Nanomedicine

The University of Chicago

United States

Postdoctoral Scholar :: Chemistry

Education History

University of Pittsburgh

United States

PHD :: Pharmaceutics

Publications

Zhiren Wang, Wenpan Li, Jianqin Lu
Sphingomyelin-derived epacadostat nanovesicle enhances IDO1 inhibition for improved melanoma combination immunotherapy. Genes and immunity (2024)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, Qing-Yu Zhang, Jianqin Lu
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nature communications 15 (1) (2024)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, Qing-Yu Zhang, Jianqin Lu
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nature communications 15 (1) (2024)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, Qing-Yu Zhang, Jianqin Lu
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nature communications 15 (1) (2024)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, Qing-Yu Zhang, Jianqin Lu
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nature communications 15 (1) (2024)
Zhiren Wang, Wenpan Li, Jianqin Lu
Sphingomyelin-derived epacadostat nanovesicle enhances IDO1 inhibition for improved melanoma combination immunotherapy. Genes and immunity (2024)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, Qing-Yu Zhang, Jianqin Lu
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nature communications 15 (1) (2024)
Zhiren Wang, Karina Marie Gonzalez, Leyla Estrella Cordova, Jianqin Lu
Nanotechnology-empowered therapeutics targeting neurodegenerative diseases. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (2023)
Yanhao Jiang, Wenpan Li, Zhiren Wang, Jianqin Lu
Lipid-Based Nanotechnology: Liposome. Pharmaceutics 16 (1) (2023)
Yanhao Jiang, Wenpan Li, Zhiren Wang, Jianqin Lu
Lipid-Based Nanotechnology: Liposome. Pharmaceutics 16 (1) (2023)
Yanhao Jiang, Wenpan Li, Zhiren Wang, Jianqin Lu
Lipid-Based Nanotechnology: Liposome. Pharmaceutics 16 (1) (2023)
Zhiren Wang, Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Leyla Estrella Cordova, Jinha Chung, Minhyeok Kim, Georg T Wondrak, Jennifer Erdrich, Jianqin Lu
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy. Nature communications 14 (1) (2023)
Yanhao Jiang, Wenpan Li, Zhiren Wang, Jianqin Lu
Lipid-Based Nanotechnology: Liposome. Pharmaceutics 16 (1) (2023)
Zhiren Wang, Leyla Estrella Cordova, Pavani Chalasani, Jianqin Lu
Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. Molecular pharmaceutics 19 (12) (2022)
Wenpan Li, Karina Marie Gonzalez, Jinha Chung, Minhyeok Kim, Jianqin Lu
Surface-modified nanotherapeutics targeting atherosclerosis. Biomaterials science 10 (19) (2022)
Zhiren Wang, Nicholas Little, Jiawei Chen, Kevin Tyler Lambesis, Kimberly Thi Le, Weiguo Han, Aaron James Scott, Jianqin Lu
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nature nanotechnology 16 (10) (2021)
Wenpan Li, Nicholas Little, Jonghan Park, Cole Alexander Foster, Jiawei Chen, Jianqin Lu
Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Molecular pharmaceutics 18 (8) (2021)
Qi Liu, Xiang Wang, Xiangsheng Liu, Sanjan Kumar, Grant Gochman, Ying Ji, Yu-Pei Liao, Chong Hyun Chang, Wesley Situ, Jianqin Lu, Jinhong Jiang, Kuo-Ching Mei, Huan Meng, Tian Xia, André E Nel
Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model. ACS nano 13 (4) (2019)
Jianqin Lu, Xiangsheng Liu, Yu-Pei Liao, Xiang Wang, Ayman Ahmed, Wen Jiang, Ying Ji, Huan Meng, André E Nel
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS nano 12 (11) (2018)
Xiangsheng Liu, Jinhong Jiang, Ryan Chan, Ying Ji, Jianqin Lu, Yu-Pei Liao, Michael Okene, Joshua Lin, Paulina Lin, Chong Hyun Chang, Xiang Wang, Ivanna Tang, Emily Zheng, Waveley Qiu, Zev A Wainberg, André E Nel, Huan Meng
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. ACS nano 13 (1) (2018)
Jianqin Lu, Xiangsheng Liu, Yu-Pei Liao, Felix Salazar, Bingbing Sun, Wen Jiang, Chong Hyun Chang, Jinhong Jiang, Xiang Wang, Anna M Wu, Huan Meng, Andre E Nel
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nature communications 8 (1) (2017)

Jianqin Lu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jianqin Lu